Becker's Healthcare October 2, 2024
Eli Lilly is building a $4.5 billion facility in Indiana that will combine research and production, aiming to enhance manufacturing efficiency and accelerate the development of clinical trial medicines, the drugmaker said Oct. 2.
Four things to know:
- The Lilly Medicine Foundry, set to open in 2027, is being constructed in Lebanon, Ind., near another multibillion-dollar manufacturing site that produces tirzepatide, the active ingredient in its blockbuster GLP-1 drugs, Mounjaro and Zepbound.
- Eli Lilly described the new center as a first-of-its-kind facility that will combine research and manufacturing in a single location.
“This unique facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for...
Today's Sponsors
Today's Sponsor